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ta.2012.1Abstract Introduction: This phase II clinical trial aimed to investigate the efﬁcacy and safety of
induction chemotherapy with docetaxel, cisplatin and 5-ﬂuorouracil (TPF regimen) followed by
concurrent chemoradiation in patients with locally advanced nasopharyngeal carcinoma.
Methods: Eligible patients were aged 15–70 years and had to have newly diagnosed locally advanced
NPC (T3–T4and/orN2–N3,M0),KarnofskyPerformance Status (KPS)P70, and normal or adequate
kidney, liver, cardiovascular, and bone marrow functions. All patients were assigned to receive 3 cycles
of induction chemotherapy in an outpatient setting every 3 weeks with TPF regimen (docetaxel 75
mg/m2 for day 1, cisplatin 75 mg/m2 for day 1, 5-FU 750 mg/m2/day with 8-h infusion on days 1–3)
followed by 7 weeks of concurrent chemoradiation (70 Gy) with weekly cisplatin 30 mg/m2.Colorectal Research Center,
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108 N. Ahmadloo et al.Results: Overall, 74 courses of induction chemotherapy were administered. After induction chemo-
therapy, overall response rate was 84%. However, only one patient achieved a pathologic complete
response. At the end of concurrent chemoradiation, 24 patients (96%) achieved clinical and pathologic
complete response at both nasopharynx and regional nodes and one (4%) had persistent disease. Treat-
ment-related toxicitieswere commonbutmanageable.Grade 1–2 anemiawas themost hematologic tox-
icity being detected in 51 cycles (68.9%) of induction chemotherapy. Four patients developed
uncomplicated, culture-negative febrile neutropenia. There was no treatment-related death.
Conclusion: Induction chemotherapy with TPF regimen followed by concurrent chemoradiation is
highly effective with manageable toxicity in patients with locally advanced nasopharyngeal carcinoma.
ª 2012 Egyptian Society of Ear, Nose, Throat and Allied Sciences.
Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Despite the low incidence rate of nasopharyngeal carcinoma
(NPC), the age distribution for NPC is younger than that for
other head and neck sites. Approximately 20% of the patients
are younger than 30 years of age.1 It is also the most frequent
carcinoma of the head and neck malignancy in pediatric and
young adolescent population.2 Locally advanced NPC refers
to a group of NPCs demonstrating advanced disease in naso-
pharynx or regional lymph nodes without evidence of distant
metastasis. Approximately 50% of NPCs are locally advanced
at presentation.3 Compared to other head and neck cancers,
surgery plays a limited role in treating NPC. Distinctive ana-
tomical location and vicinity of NPC to skull base neurovascu-
lar structures prevent curative surgery.4,5 However, NPC is a
highly radiosensitive tumor and radical external beam radio-
therapy with or without chemotherapy remains the mainstay
of treatment for this neoplasm. Concurrent chemoradiation
is currently the standard of care for locoregionally advanced
NPCs.5 Locoregional and systemic failures are high in patients
with locally advanced disease and contribute to poor sur-
vival.4–6 Consequently, more effective chemotherapeutic regi-
mens and other systemic therapy are needed to decrease the
rate of locoregional and distant failure and improve survival.
Previous studies conﬁrmed the efﬁcacy and the feasibility of
induction chemotherapy with docetaxel, cisplatin and 5-ﬂuoro-
uracil (TPF regimen) regimen in locally advanced head and
neck cancers.7,8 In addition, the tolerability and efﬁcacy of con-
current chemoradiation with weekly cisplatin have been proven
in patients with locally advanced NPC. The present phase II
clinical trial aimed to investigate the response rates of induction
chemotherapy with TPF regimen followed by concurrent che-
moradiation in treatment of locally advanced NPCs.2. Patients and methods
This phase II clinical trial enrolled 28 patients with diagnosis of
NPC who were referred to Namazi academic hospital for treat-
ment between April 2011 and March 2012. Eligible patients
were aged between 15 and 70 years and had to have newly
diagnosed locally advanced NPC stage classiﬁcation III–IVB
(T3–T4 and/or N2–N3, M0) based on the criteria used in the
7th edition of the American Joint Committee on Cancer
(AJCC) Staging system,9 Karnofsky Performance Status
(KPS) P70, and normal or adequate kidney, liver, cardio-
vascular, and bone marrow functions. In this study we
considered a serum creatinine <1.4 mg/dl, and creatinineclearance >60 ml/min as adequate renal function. The study
was approved by the Clinical Research Ethics Committee of
Shiraz University of Medical Sciences in accordance with The
Code of Ethics of the World Medical Association (Declaration
of Helsinki) for experiments involving humans. Written
informed consent was obtained from all patients before trial
entry. Exclusion criteria were prior therapy, any evidence of
distant metastases before or during the trial, known contraindi-
cation for chemotherapy (such as allergy to taxan drugs),
positive history of receiving radiotherapy for other head and
neck neoplasms, documented heart, liver, renal or blood
coagulation diseases, and patients’ refusal to participate in the
trial or to sign on the consent form.
2.1. Patient evaluation
Pre-treatment evaluation included a complete medical history,
physical examination with special attention on the status of
cervical lymph nodes regarding their size, location and ﬁxa-
tion, assessment of KPS, direct nasopharyngoscopy to deter-
mine tumor extension and taking biopsy, chest radiograph,
ultrasound imaging of the abdomen and contrast-enhanced
Computed Tomography (CT) scan of the nasopharynx and
neck. Disease staging was deﬁned according to the 7th edition
of AJCC staging system.9 Other tests included complete blood
count (CBC), liver function tests (LFT) and renal function test
(RFT). Baseline audiogram was performed for all patients.
Whole body bone scintigraphy was performed in symptomatic
patients or those with elevated alkaline phosphatase level. In
addition, cardiovascular evaluation was carried out in high
risk patients (age greater than 60 years, heavy smoker and
background diseases like hypertension or diabetes mellitus).
All patients were carefully evaluated for dental carry and all
needed dental repairs and treatment were completed well be-
fore starting radiation therapy.
2.2. Treatment
All patients were assigned to receive induction chemotherapy
in an outpatient setting every 3 weeks for 3 cycles with TPF
regimen (docetaxel 75 mg/m2 for day 1, cisplatin 75 mg/m2
for day 1, 5-FU 750 mg/m2/day with 8-h infusion on days
1–3). Antiemetic medication including a selective 5-hydroxy-
tryptamine-3 (5HT3) antagonist and steroids were prescribed
intravenously for all chemotherapy cycles. In addition, pro-
phylactic colony stimulating factor (as 5 lg/kg ﬁlgrastim)
was considered for all patients following each cycle of TPF
regimen during days 5–9. Clinical condition, regional lymph
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Table 1 Patients and disease characteristics.
Characteristics Patients no. (%)
Total patients 25 (100)
Age (year)
Range 16–68
Median 42
Mean ± SD 40.52 ± 14.27
Sex
Male 16 (64)
Female 9 (36)
Presenting signs and symptoms
Neck mass 15 (60)
Epistaxis 5 (20)
Cranial nerve palsy 5 (20)
WHO pathologic classiﬁcation
Type I 5 (20)
Type II 16 (64)
Type III 4 (16)
Primary tumor stage
T1 1 (4)
T2 2 (8)
T3 15 (60)
T4 7 (28)
Cervical lymph node stage
No 6 (24)
N1 8 (32)
N2 5 (20)
N4 6 (24)
AJCC stage
III 17 (68)
IVA 2 (8)
IVA 6 (24)
AJCC, American Joint Committee on Cancer.node status, treatment toxicity and patients’ complaints were
evaluated and recorded before each cycle of chemotherapy.
Three weeks after completion of induction chemotherapy,
all patients were assigned to receive concurrent chemoradia-
tion with weekly cisplatin (30 mg/m2) from the ﬁrst day of
radiation therapy (RT), up to 7 cycles. External beam RT
using megavoltage telecobalt unit or linear accelerator (6
MV) was performed. The nasopharynx and regional cervical
lymph nodes were treated with conventional fractionation
and a total dose of 70 Gy was delivered in 35 fractions (5 frac-
tions per week). The primary site and upper cervical lymph
nodes were treated with two lateral parallel opposed ﬁelds;
and the lower cervical lymph nodes were treated with a sepa-
rate en face anterior ﬁeld with a central block. The spinal cord
was excluded from the radiation ﬁelds after 44 Gy. After
50 Gy, RT was continued to the primary site up to 70 Gy.
Metastatic lymph nodes received a boost dose of 15–20 Gy.
Each cycle of induction chemotherapy or weekly cisplatin
was administered only if the general condition of the patient
and blood tests were acceptable (HbP 9 g/dl, absolute neutro-
phil count [ANC]P 1500, plateletP 100000, SGPT, SGOT,
ALP 6 1.5 fold of normal upper limit, normal bilirubin and
creatinine). Tumor response was evaluated at the end of induc-
tion chemotherapy and again 4 weeks after completion of con-
current chemoradiation. Response evaluation included clinical
examination and CT scan of the nasopharynx. In addition, in
patients with complete clinical and radiologic response, direct
nasopharyngoscopy and biopsy of the nasopharynx were done
to evaluate the pathologic response. All CT scan images were
reviewed by the same radiologist.
Tumor response evaluation was based on Response Evalu-
ation Criteria In Solid Tumors (RECIST) as follows: complete
response was deﬁned as the complete disappearance of all
assessable lesions; partial response as over 30% reduction in
the sum of the longest diameters of all measurable disease com-
pared with baseline; stable disease as less than 30% reduction
or less than 20% increase in the sum of the longest diameters
of all measurable disease; and progressive disease was deﬁned
as more than 20% increase in the longest diameters of original
measurable disease or the appearance of a new lesion.10 Treat-
ment complications during induction chemotherapy and con-
current chemoradiation were recorded using version 4.0 (the
last version) of Common Terminology Criteria for Adverse
Events (CTCAE). Clinical response rates and safety were the
primary and secondary endpoints, respectively.
2.3. Statistical methods
The chi-squared (v2), Fisher’s exact, and Mann–Whitney tests
were used for comparing the clinical response rates and the clin-
icopathological characteristics of the trial arms. The statistical
analysis was performed according to the sum of the longest
diameters of all measurable lesions. A minimum sample size re-
quired 24 patients to ensure 80% power with 5% conﬁdence
interval. Data analyses were done with Wilcoxon and Fried-
man tests, and carried out using SPSS Software, version 17.
3. Results
Twenty eight patients with locally advanced NPC were enrolled
in this study. After excluding three patients who developedskeletal metastases or refused to continue induction chemother-
apy 25 patients participated in the study. Patient characteristics
are listed in Table 1.
Overall, 74 courses of induction chemotherapy with TPF
regimen were administered for the patients. Only one of the
patients could not receive the third cycle of induction chemo-
therapy because of severe drug reaction to docetaxel (grade 4
dyspnea) during the second course of chemotherapy.
Three weeks after the last cycle of induction chemotherapy,
12 patients (48%) achieved a clinical complete response and 10
(40%) achieved a clinical partial response. Therefore, after
induction chemotherapy, overall response rate was 84%. How-
ever, direct nasopharyngoscopic and pathologic examination
revealed that only one patient (4%) achieved a pathologic
complete response and 20 (80%) achieved a partial response
and residual disease in the nasopharynx. The overall (complete
and partial) clinical and pathologic response rates to neoadju-
vant chemotherapy were 88% and 84% respectively (Table 2).
Subsequently the patients received a median total radiation
dose of 70 Gy (range 64–70 Gy) concurrently with median 6
cycles (range 4–7 cycles) of weekly cisplatin. Four weeks after
completing concurrent chemoradiation, 21 patients (82%)
achieved a clinical complete response at both nasopharynx
and regional nodes and 4 (18%) showed residual nasopharyn-
geal soft tissue in CT scan (Table 2). However, in direct naso-
Table 4 Toxicity-related to concurrent chemoradiation.
Toxicity Number of patients (%)
Grade 1–2 Grade 3–4
Hematologic
Anemia 20 (80) 1 (4)
Neutropenia 11 (44) 3 (12)
Thrombocytopenia 6 (24) –
Non-hematologic
Nausea 15 (60) 10 (40)
Vomiting 4 (16) –
Xerostomia 20 (80) 5 (20)
Oral mucositis 19 (76) 6 (24)
Dermatitis 25 (100) –
Sensory neuropathy 4 (16) –
110 N. Ahmadloo et al.pharyngoscopy and pathologic examination only one patient
had persistent disease and the three remaining patients showed
no evidence of malignancy and there was chronic inﬂammation
and necrosis. Therefore, by considering these results, after
completion of the therapy 24 patients (96%) achieved a path-
ologic complete response.
Overall, treatment-related toxicities were common but man-
ageable (Table 3). During 74 cycles of chemotherapy grade 1–2
anemia was the most hematologic toxicity, being detected in 51
cycles (68.9%). Four patients developed uncomplicated, cul-
ture-negative febrile neutropenia. Grade 3 nausea and diarrhea
occurred in 8.1% and 1.35% of the cycles, respectively.
Toxicity related to concurrent chemoradiation was tolerable
(Table 4), with grade 3 neutropenia and anemia occurred in
12% and 4% of patients, respectively. Grade 3 nausea, oral
mucositis and xerostomia developed in 40%, 24%, and 20%
of patients, respectively. Due to these non-hematologic toxici-
ties, radiotherapy was interrupted in 8 patients (32%) and ﬁnal-
ly stopped before 70 Gy in 5 patients (20%). There was no
treatment-related death.
4. Discussion
NPC has different epidemiologic and biologic features than
those of other head and neck SCCs.11,12 It is more commonTable 3 The rate of chemotherapy-related toxicity during 74 cycles
Toxicity Number of ind
Grade 1–2
Hematologic
Anemia 51 (68.91)
Neutropenia 28 (37.83)
Thrombocytopenia 10 (13.51)
Neutropenic fever –
Non-hematologic
Nausea 31 (41.89)
Vomiting 7 (9.45)
Diarrhea 15 (20.27)
Sensory neuropathy 19 (25.67)
Dyspnea –
Table 2 Response rates to induction chemotherapy and chemoradi
Mode of response rate assessment Patients no
After induc
CT scan and physical exam
Complete response 12 (48)
Partial response 10 (40)
Persistent disease 3 (12)
Progressed disease 0 (0)
Endoscopic and pathologic examination
Complete response 1 (4)
Partial response 20 (80)
Persistent disease 4 (16)
Progressed disease 0 (0)
Overall response (CR+ PR) 22 (88)
CR, complete response; PR, partial response; CT, computed tomographyin china and is rare in west countries.12 Locally advanced
NPCs tend to develop high rates of locoregional and distant
failure and have poor prognosis. The 5-year survival rate with
radiotherapy alone is 15-50%.12,13 Early studies found that
sequential chemotherapy with cisplatin and 5-ﬂuorouracil fol-
lowing radiotherapy alone or chemoradiation induced higher
rates of complete response and better survival. However, thisof induction chemotherapy.
uction chemotherapy cycles (%)
Grade 3–4
–
7 (9.5)
–
4 (5.4)
6 (8.1)
–
(1.35)
–
1 (1.35)
ation therapy.
. (%)
tion chemotherapy After chemoradiation
21 (82)
3 (12)
1 (4)
0 (0)
24 (96)
0 (0)
1 (4)
0 (0)
24 (96)
.
Table 5 Clinical trials evaluating induction chemotherapy followed by concurrent chemoradiation in advanced nasopharyngeal
carcinoma.
Author Pts no. Stage Induction ChT regimen Response (%) DFS–PFS OS Major toxicity
Partial Complete
Johnson17 18 III DC · 3 cycles 78 11 – – Hematologic
Bae18 33 III-IVB TPF · 3 cycles 15 82 76 (3y) 86 (3y) Hematologic
Bossi19 30 – TPF · 3 cycles – – 79 (3y) 87 (3y) GI, Hematologic
Chen20 22 M+ TXP 63 9 – – Hematologic
Chua21 19 M+ TP 56 6 – – Hematologic
Du22 60 III-IVB TPF 5 93 90 (3y) 98 (2y) Hematologic
Ekenel23 59 II-IVB TP – – 85 (3y) 95 (3y) –
Huang24 56 R/M+ TPF · 4-6 cycles 53 29 – – Hematologic, GI
McCarthy25 9 R/M+ TP · 5 cycles 22 – – – Hematologic
Varan26 10 II-IVB TP · 4 cycles 50 10 70 (2y) 90 –
Hui14 34 – TP – – 88 (3y) 94 Hematologic
Chan15 31 III-IVB PC · 2 cycles 39 58 – – –
Kong27 59 III-IVB TPF · 3 cycles – 20 – – Hematologic, GI
Present study 25 III-IVB TPF · 3 cycles 84 4 – – Hematologic, GI
Pts, patients; ChT, chemotherapy; DFS, disease free survival; PFS, progression free survival; OS, overall survival; TC, docetaxel + carboplatin;
TPF, docetaxel + cisplatin + 5-ﬂuorouracil; GI, gastrointestinal; R, recurrent; M+, distant metastasis; TXP, docetaxel + capecita-
bine + cisplatin; TP, docetaxel + cisplatin; PC, paclitaxel + cisplatin.
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creased toxicity.12,13 Induction chemotherapy followed by con-
current chemoradiation is more likely to be successfully
administered than adjuvant chemotherapy following concur-
rent chemoradiation. Therefore, recent trials focused on induc-
tion chemotherapy and showed promising results of induction
cisplatin-based chemotherapy followed by concurrent chemo-
radiation in treatment of locally advanced NPCs. However,
overall survival was not statistically signiﬁcant.14
The goal of induction chemotherapy in NPC is to eradicate
micrometastasis, downstaging the primary tumor and meta-
static regional lymph nodes and improve response rate to the
chemoradiation.12,13 The other probable beneﬁt of neoadju-
vant chemotherapy is improvement in radiation delivery to tar-
get.12 Rischin et al, in a phase II trial evaluated the effect of 3
cycles of neoadjuvant epirubicin, cisplatin, 5-ﬂuorouracil
(ECF) followed by chemoradiation in locally advanced NPC.
Overall clinical response was 89% and complete clinical re-
sponse was 40%. The 4-year progression-free and overall sur-
vival rates were 81% and 90% respectively.12
Subsequent clinical trials found that the addition of doce-
taxel or paclitaxel to cisplatin and 5-ﬂuorouracil induction che-
motherapy improved the efﬁcacy of induction chemotherapy
with manageable toxicities in patients with NPCs.15,16 Guo
et al in a phase I study tried to deﬁne the best tolerable dose
for TPF regimen. They started induction chemotherapy with
docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1, and
5-FU 400 mg/m2 days 1–5. They gradually escalated the doses
and found neutropenia , mucositis and diarrhea were the dose
limiting factors. Finally, they recommended docetaxel 60
mg/m2 day 1, cisplatin 60 mg/m2 day 1, and 5-FU 600 mg/m2
days 1–5.17 In our study, the dose of drugs was docetaxel
75 mg/m2, cisplatin 75 mg/m2 and 5-FU 750 mg/m2 for 3 days.
There are multiple clinical trials evaluating induction cis-
platin-based chemotherapy with taxanes followed by concur-
rent chemoradiation in locally advanced or metastatic
nasopharyngeal carcinoma,15,16,18–28 Table 5). These promis-
ing results showed that the addition of a taxane (docetaxel,paclitaxel) to cisplatin-based induction chemotherapy im-
proved response rates and survival rates. In addition, this table
shows that hematologic (particularly neutropenia) and gastro-
intestinal (particularly mucositis, diarrhea and emesis) toxici-
ties are the most important adverse effects.
The response rates to therapy and major toxicity of the
present study were consistent with other studies (Table 5).5. Conclusion
Induction chemotherapy with TPF is highly effective with
acceptable and manageable toxicity in treating patients with
locally advanced nasopharyngeal carcinoma. Further follow-
ups are needed to translate these results into an advantage in
overall survival.Acknowledgement
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